Psoriatic Arthritis with ≤4 Swollen Joints: What to Do When a JAK Inhibitor Has Not Worked
This protocol covers peripheral monoarthritis or oligoarthritis (≤4 swollen joints) without poor prognostic factors, at the stage where a prior JAK inhibitor has not achieved the required clinical target.
Prior Treatment & Failure Condition
The preceding step used a JAK inhibitor (tofacitinib or upadacitinib, with safety considerations applied). This protocol is indicated when that therapy did not reach:
- Improvement at 3 months, or
- Remission or low disease activity at 6 months
Clinical Scenario
Peripheral monoarthritis or oligoarthritis with ≤4 swollen joints and no poor prognostic features: no structural damage, no elevated acute phase reactants, no dactylitis, no nail involvement. This presentation carries a more favourable long-term prognosis compared with higher-risk phenotypes.
Next Step & Treatment Targets
The approach involves switching to a different class of biologic or targeted therapy — with one within-class switch also an option. The clinical goals remain unchanged:
- Improvement at 3 months
- Remission or low disease activity at 6 months
Specific agent selection and the full decision sequence are detailed in the structured regimen.
References
DOI: 10.1136/ard-2024-225531
- Patients with oligoarticular disease and lack of poor prognostic factors should also receive a csDMARD, but there is less urgency for these patients given the more favourable long-term prognosis.
- The latter may receive csDMARDs after a longer delay, and potentially a period of symptomatic treatment alone.
- In patients with an inadequate response or intolerance to a bDMARD or a JAKi, switching to another bDMARD or JAKi should be considered, including one switch within a class.
- Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.
View source ↗